Compare DEA & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEA | NKTR |
|---|---|---|
| Founded | 2011 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2014 | 1996 |
| Metric | DEA | NKTR |
|---|---|---|
| Price | $21.71 | $36.11 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 15 |
| Target Price | $25.21 | ★ $131.92 |
| AVG Volume (30 Days) | 357.4K | ★ 564.8K |
| Earning Date | 10-26-2026 | 11-12-2026 |
| Dividend Yield | ★ 8.22% | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $336,099,000.00 | $307,711,000.00 |
| Revenue This Year | $8.22 | N/A |
| Revenue Next Year | $2.29 | $32.51 |
| P/E Ratio | $109.45 | ★ N/A |
| Revenue Growth | 11.27 | ★ 86.00 |
| 52 Week Low | $20.56 | $33.40 |
| 52 Week High | $25.96 | $109.00 |
| Indicator | DEA | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 37.01 | 35.65 |
| Support Level | $21.35 | $35.68 |
| Resistance Level | $23.60 | $40.12 |
| Average True Range (ATR) | 0.46 | 1.65 |
| MACD | -0.07 | 0.65 |
| Stochastic Oscillator | 8.89 | 17.19 |
Easterly Government Properties Inc is a real estate investment trust. The company is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. It generates all its revenue by leasing its properties to such agencies. The company operates in single segment for the purposes of assessing performance and making operating decisions.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.